Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
RATIONALE: Autologous stem cell transplantation may be effective treatment for primary
 systemic (AL) amyloidosis.

 PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell
 transplantation works in treating patients with primary systemic (AL) amyloidosis.
OBJECTIVES:

 -  Determine the tolerability of tandem autologous stem cell transplantation in patients
 with AL amyloidosis.

 -  Determine whether this regimen can convert a hematologic non-complete response (CR) to
 CR in these patients.

 -  Determine the overall survival of patients treated with this regimen.

 OUTLINE:

 -  First transplantation: Patients receive filgrastim (G-CSF) subcutaneously once daily
 beginning 3 days before the initiation of stem cell collection and continuing until the
 day before the completion of stem cell collection. Patients may undergo bone marrow
 harvest if an inadequate number of peripheral blood stem cells are collected.

 Patients receive high-dose melphalan IV over 20 minutes on days -3 and -2. Patients undergo
 autologous stem cell transplantation (ASCT) on day 0.

 -  Second transplantation: Within 6-12 months after the first ASCT, patients not achieving
 a complete response receive high-dose melphalan IV over 20 minutes on days -3 and -2 and
 a second ASCT on day 0.

 Treatment continues in the absence of unacceptable toxicity.

 Patients are followed at 3 and 6 months, 1 year, and then annually thereafter.

 PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 2-3 years.
Inclusion Criteria:

 DISEASE CHARACTERISTICS:

 -  Histologically confirmed AL amyloidosis, meeting 1 of the following criteria:

 -  Plasma cell dyscrasia, evidenced by 1 of the following:

 -  Monoclonal protein in the serum or urine by immunofixation electrophoresis

 -  Plasmacytosis of the bone marrow with monoclonal staining for kappa or
 lambda light chain isotype

 -  Macroglossia with at least 1 other site having biopsy proven amyloidosis and
 absence of a mutant transthyretin is ruled out

 PATIENT CHARACTERISTICS:

 Age

 -  18 to 65

 Performance status

 -  SWOG 0-2

 Life expectancy

 -  At least 1 year

 Hematopoietic

 -  Not specified

 Hepatic

 -  Not specified

 Renal

 -  Not specified

 Cardiovascular

 -  LVEF ≥ 45% by MUGA or echocardiogram

 Pulmonary

 -  DLCO ≥ 50%

 Other

 -  Not pregnant or nursing

 -  Fertile patients must use effective contraception

 -  Able to tolerate 2 courses of high-dose therapy

 -  HIV negative

 PRIOR CONCURRENT THERAPY:

 Biologic therapy

 -  Not specified

 Chemotherapy

 -  Prior alkylating agent chemotherapy allowed provided there is no morphologic or
 cytogenetic evidence of myelodysplastic syndromes

 -  Prior total cumulative oral melphalan dose < 300 mg

 Endocrine therapy

 -  Not specified

 Radiotherapy

 -  Not specified

 Surgery

 -  Not specified

 Other

 -  At least 4 weeks since prior cytotoxic therapy and recovered

 Exclusion Criteria:

 -  No senile, secondary, localized, dialysis-related, or familial amyloidosis

 -  No overt multiple myeloma (e.g., greater than 30% bone marrow plasmacytosis, extensive
 [more than 2] lytic lesions, hypercalcemia)

 Cardiovascular

 -  No myocardial infarction within the past 6 months

 -  No congestive heart failure

 -  No arrhythmia refractory to therapy

 -  No evidence of symptomatic transient ischemic attacks or strokes

 -  No other malignancy within the past 5 years except adequately treated basal cell or
 squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
 stage I or II cancer currently in complete remission